Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 40 of the 42 references it cites were found in a registry or an index.

PAK and PI3K pathway activation confers resistance to KRASG12C inhibitor sotorasib

Open access

Abstract

Background KRAS is a frequently mutated oncogene in human cancer. Clinical studies on the covalent inhibitors of the KRAS G12C mutant have reported promising results. However, primary and acquired resistance may limit their clinical use.Methods Sotorasib-resistant cell lines were established. We explored the signalling pathways activated in these resistant cell lines and their roles in sotorasib resistance.Results The resistant cells exhibited increased cell-matrix adhesion with increased levels of stress fibres and focal adherens. p21-activated kinases (PAKs) were activated in resistant cells, which phosphorylate MEK at serine 298 of MEK and serine 338 of c-Raf to activate the mitogen-activated protein kinase pathway. The PAK inhibitors FRAX597 and FRAX486 in synergy with sotorasib reduced the viability of KRAS G12C mutant cancer cells. Furthermore, the PI3K/AKT pathway was constitutively active in sotorasib-resistant cells. The overexpression of constitutively activated PI3K or the knockdown of PTEN resulted in resistance to sotorasib. PI3K inhibitor alpelisib was synergistic with sotorasib in compromising the viability of KRAS G12C mutant cancer cells. Moreover, PI3K and PAK pathways formed a mutual positive regulatory loop that mediated sotorasib resistance.Conclusions Our results indicate that the cell-matrix interaction-dependent activation of PAK mediates resistance to sotorasib through the activation of MAPK and PI3K pathways.

Overview

Integrity signals

Registry

Crossref · 10.1038/s41416-022-02032-w

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 42 references

Research works printed but not linked: 1

  1. Rodenhuis S. Ras and human tumors. Semin Cancer Biol. 1992;3:241–7.

Cited by

See all 56

Metadata

Authors
Chan, C.-H., Chiou, L.-W., Lee, T.-Y., Liu, Y.-R., Hsieh, T.-H., Yang, C.-Y., & Jeng, Y.-M.
Affiliations
  • National Taiwan University (TW)
  • Taipei Medical University (TW)
Corresponding author
  • Yang, Ching-Yao
  • Jeng, Yung-Ming
Venue
British Journal of Cancer
Published
2022-11-01
Volume
128
Issue
1
Pages
148-159
ISSN
  • 0007-0920 (ISSN-L)
  • 1532-1827
OpenAlex
W4307975982
Cited by
56
References
42
Citations by year
2026: 8 · 2025: 22 · 2024: 15 · 2023: 11
FWCI
3.92
Type
journal article
Language
en
Open access
Licence
Locations
  • British Journal of Cancer (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
Ministry of Science and Technology, Taiwan (109-2314-B-002-084, 110-2314-B-002-173)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Keywords
KRAS G12C, sotorasib, drug resistance, p21-activated kinase, PI3K/Akt signaling, MEK phosphorylation, Raf-1, MAPK signaling, cell-matrix adhesion, stress fibers, focal adhesions, PTEN, alpelisib, combination therapy, KRAS inhibitor resistance
MeSH terms
Humans, Lung Neoplasms, Mutation, Piperazines, Pyridines, Pyrimidines, Proto-Oncogene Proteins p21(ras), Drug Resistance, Neoplasm, Phosphatidylinositol 3-Kinases, Mitogen-Activated Protein Kinase Kinases, Cell Line, Tumor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: PAK and PI3K pathway activation confers resistance to KRASG12C inhibitor sotorasib. https://app.cochat.ai/papers/10.1038/s41416-022-02032-w
The paper
Chan, C.-H., Chiou, L.-W., Lee, T.-Y., Liu, Y.-R., Hsieh, T.-H., Yang, C.-Y., & Jeng, Y.-M. (2023). PAK and PI3K pathway activation confers resistance to KRASG12C inhibitor sotorasib. British Journal of Cancer. https://doi.org/10.1038/s41416-022-02032-w

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.